"Prepared for distribution at the Developments in Pharmaceutical and Biotech Patent Law 2017 Program, New York City, November 1, 2017" -- Page 5. "#186667"-- Back cover. Index begins with letter B and is erratic. Includes bibliographical references and index.
Contents:
Section 101 : patentable subject matter in the aftermath of Myriad and Myro/ / Jennifer Gordon, Jacob L. Stanley, Eileen M. Woo. Excerpt from Ch. 5 : patentability, Practicing Law Institute, pharmaceutical and biotech patent law, Section 5:4.5 (C) (November 2016) / Daniel L. Reisner -- Excerpt from Ch. 7 : Types of biological and pharmaceutical patents, Practicing Law Institute, pharmaceutical and biotech patent law, Section 7:7 (November 2016) / Daniel L. Reisner -- Ethical issues confronting life sciences patent lawyers / Sanjay K. Murthy -- The changing scope of prior art : what's new, what's in, what's out (substantive outline) / Kenneth H. Sonnenfeld, Ph.D., Paula K. Wittmayer -- Strategic approaches to the interplay between Hatch-Waxman litigation and Inter partes review / Reilly Falanga LLP -- Section 101 : patentable subject matter in the aftermath of Myriad and Myro/ / Jennifer Gordon, Jacob L. Stanley, Eileen M. Woo.
Series:
Intellectual property course handbook series ; G-1341
This resource is supported by the Institute of Museum and Library Services under the provisions of the Library Services and Technology Act as administered by State Library of Iowa.